• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

7 diabetes treatment innovations to look out for on World Diabetes Day

November 15, 2021 By Sean Whooley

Senseonics’ next-gen CGM

Eversense CGM Senseonics
The Eversense CGM [Image courtesy of Senseonics]
Senseonics (NYSE:SENS) has high expectations for its longer-duration CGM following positive results from the Promise study that were presented in June. After presenting the company’s third-quarter earnings, President & CEO Tim Goodnow said Senseonics hopes for FDA approval soon.

The next-generation Eversense CGM demonstrated matching performance levels compared to the current 90-day sensor available in the U.S., but with reduced calibration, down to one per day, with duration extended to 180 days. The company says its system offers a fluorescence-based sensor, a smart transmitter worn over the sensor for facilitating data communication and a mobile app that displays glucose values, trends and alerts.

Senseonics touts Eversense as the first CGM system to feature a smart transmitter that gives wearers discreet, on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor.

“We are encouraged by the excitement demonstrated by patients and HCPs for the 180-day sensor in the U.S. and we are pleased with the progression of the review and are hopeful the FDA will reach an approval decision in the coming months based on the positive Promise study results,” Goodnow said. “We look forward to launching the new system shortly after approval.”

Next>>

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pharmaceuticals Tagged With: Dexcom, Diabeloop, Eli Lilly, Eli Lilly & Co., Fractyl Health, Insulet, Medtronic, Senseonics, Twin Health

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS